You are here: Industry Insights > Pfizer

News List

Pfizer, Arvinas Forge $830M Protein Degradation R&D Deal biospace
January 05, 2018
Two months after expanding a licensing deal with Genentech, privately-held Arvinas LLCstruck another lucrative deal with a major pharmaceutical company
Sangamo, Pfizer Deepen Relationship With New $162M ALS R&D Pact biospace
January 04, 2018
Earlier today, Sangamo Healing announced a $ 162 million agreement with Pfizer
US green light for Pfizer/Merck diabetes therapies pharmatimes
January 03, 2018
Pfizer and Merck’s diabetes drugs Steglatro and Steglujan have been approved for the US market.
Boston Startup Centrexion by Pfizer's Ex-CEO grants $67M for Ph3 Osteoarthritis Pain Drug biospace
January 03, 2018
Centrexion Therapeutics closed on a Series D financing worth $67 million to develop its knee osteoarthritis (OA) drug in Phase III.
Breakthrough status for Pfizer/Merck’s avelumab combo pharmatimes
December 25, 2017
Merck and Pfizer’s avelumab has picked up its second breakthrough therapy status in the US, this time for use in combination with Inlyta for treatment-naïve patients with advanced renal cell carcinoma (RCC).
9 Reasons to Buy Pfizer in 2018 and 1 Big One Not To biospace
December 25, 2017
The end of 2017 isn’t likely to include too many surprises, like today’s announcement that Roche was buying San Diego-based Ignyta for $1.7 billion.
Pfizer's Bosulif scores US green light in leukaemia sub-type pharmafile
December 22, 2017
Pfizer has atment of newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia in adult patients.revealed that its tyrosine kinase inhibitor Bosulif (bosutinib) has been awarded marketing authorisation from the FDA in t
FDA Approves New Type 2 Diabetes Drug From Merck, Pfizer biospace
December 22, 2017
The U.S. Food and Drug Administration approved Merck’s and Pfizer’s Steglatro (ertugliflozin), a sodium-glucose co-transporter 2 (SGLT2)- inhibitor, that will square off against established drugs in the market.
Pfizer’s Xeljanz wins US nod for psoriatic arthritis pharmatimes
December 19, 2017
Pfizer Xeljanz and Xeljanz XR have received US marketing clearance for the treatment of adults with active psoriatic arthritis (PsA) who have failed to respond or are intolerant to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).
Why Pfizer Could and Should Scoop Up Celgene in 2018 biospace
December 06, 2017
Pfizer is no stranger to taking the big gambles—note the company’s attempts to buy AstraZeneca in 2014 and Allergan in 2016

Previous page 1 2 3 4 5 6 7 8 9 10 ... 83 84 Next page